Once E3 tags CYP17A1, the cell uses its proteasome to break down the enzyme entirely. One major advantage of PROTACs is that ...

Men diagnosed with prostate cancer have traditionally faced two choices: do nothing and hope the tumor doesn’t grow between ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.

New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...

Prostate cancer, the second leading cause of cancer death in men, sees advancements in treatment that reduce side effects, ...

Scientists have uncovered a critical weakness in prostate cancer’s defences. The disease relies on two enzymes, PDIA1 and ...

A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.

A groundbreaking new study has found that a combination of two drugs can boost survival rates in prostate cancer patients by ...

Prostate and skin cancers are among the most common cancers affecting men. In Advanced Prostate Cancer, lifelong treatment ...

A new trial will look at whether selecting patients who may require more intensive treatment can improve outcomes for advanced prostate cancer.

The FDA-approved drug Pluvicto offers hope for advanced prostate cancer patients, but access barriers remain despite proven effectiveness in extending survival.